Get the Stockscreener App
2.18
2.35%
0.05
Kalaris Therapeutics Inc stock is traded at $2.18, with a volume of 29,558.
It is up +2.35% in the last 24 hours and down -31.88% over the past month.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
See More
Previous Close:
$2.13
Open:
$2.2
24h Volume:
29,558
Relative Volume:
0.32
Market Cap:
$51.89M
Revenue:
Net Income/Loss:
$-44.10M
P/E Ratio:
-1.0201
EPS:
-2.1371
Net Cash Flow:
$-49.09M
1W Performance:
-12.80%
1M Performance:
-31.88%
6M Performance:
-62.86%
1Y Performance:
-55.78%
1-Day Range:
$2.10
$2.225
1-Week Range:
$2.11
$2.55
52-Week Range:
$2.10
$11.88
Kalaris Therapeutics Inc Stock (KLRS) Company Profile
Name
Kalaris Therapeutics Inc
Sector
Industry
Phone
650-249-2727
Address
400 CONNELL DRIVE, BERKELEY HEIGHTS
Compare KLRS vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KLRS
Kalaris Therapeutics Inc
|
2.18 | 51.89M | 0 | -44.10M | -49.09M | -2.1371 |
VRTX
Vertex Pharmaceuticals Inc
|
508.54 | 128.90B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.85 | 94.96B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
800.52 | 82.42B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.03 | 53.52B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
372.06 | 42.09B | 5.76B | 514.49M | 1.10B | 4.4813 |
Kalaris Therapeutics Inc Stock (KLRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-15-26 | Initiated | TD Cowen | Buy |
| May-14-26 | Initiated | Wedbush | Outperform |
| Apr-16-26 | Initiated | Morgan Stanley | Overweight |
| Dec-23-25 | Initiated | Chardan Capital Markets | Buy |
| Nov-03-25 | Initiated | Citizens JMP | Mkt Outperform |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| Jul-23-25 | Resumed | Piper Sandler | Neutral |
| May-07-25 | Initiated | Leerink Partners | Outperform |
| Apr-08-25 | Initiated | William Blair | Outperform |
View All
Kalaris Therapeutics Inc Stock (KLRS) Latest News
Morgan Stanley Maintains Kalaris Therapeutics(KLRS.US) With Buy Rating, Maintains Target Price $14 - Moomoo
Kalaris Therapeutics to Participate in Morgan Stanley Global Healthcare Conference Fireside Chat - Quiver Quantitative
Kalaris to Present at Morgan Stanley 24th Annual Global Healthcare Conference - Yahoo Finance
Kalaris Therapeutics (KLRS) grants VP 10,000 options to 2036 - stocktitan.net
Kalaris (KLRS) Results Breakdown: The Bottom-Line Figure Outpaces Its Comparison in the Latest Reading; Market Move: The Stock Loses 1.20% in the Current UpdateEarnings Call Highlights - vinanet.vn
Kalaris (KLRS) Results Breakdown: The Bottom-Line Figure Outpaces Its Comparison in the Latest Reading; Market Move: The Stock Loses 1.20% in the Current UpdateDividend Cut Risk - vinanet.vn
Kalaris (KLRS): Posts a 0.73% Gain to $4.15 on the Day; Range Check: the Price Remains Bounded by the Supplied Support and Resistance on the DayIV Rank - vinanet.vn
Amy O'leary Vandekop Net Worth (2026) - GuruFocus
Liisa Ann Bayko Net Worth (2026) - GuruFocus
KLRS Q1 2026 Earnings: Narrower-Than-Expected Loss Spurs 4.38% Share AdvanceEarnings Manipulation Risk - vinanet.vn
Kalaris Therapeutics Reports Q2 Financial Results, Advances Clinical Program - VisionMonday.com
Kalaris Therapeutics, Inc. 2Q 2026: Net loss $(11.5M), Diluted EPS $(0.48) — 10-Q Summary - TradingView
Kalaris Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Kalaris appoints Laurie Keating to Board of Directors - scanx.trade
Kalaris Therapeutics, Inc. (NASDAQ: KLRS) Share Price, KLRS Stock News, KLRS Share Price & Updates - Kalkine
Kalaris Therapeutics appoints Liisa Bayko as Chief Financial Officer - scanx.trade
Kalaris Therapeutics Q2 Results: EPS beats estimate, losses narrow 21% YoY - scanx.trade
Kalaris Therapeutics, Inc. (NASDAQ: KLRS) Share Price, KLRS Stock News, KLRS Share Price & Updates - kalkine.ca
Form 8K Kalaris Therapeutics Inc For: 11 August By Investing.com - Investing.com Australia
Kalaris Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Kalaris Therapeutics (NASDAQ:KLRS) Announces Earnings Results - MarketBeat
Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
Form 8K Kalaris Therapeutics Inc For: 11 August By Investing.com - Investing.com Canada
Kalaris Therapeutics Reports Q2 2026 Results and Advances Phase 1b/2 TH103 Study for Neovascular AMD - Quiver Quantitative
Kalaris Reports Q2 2026: $11.5M Quarterly Net Loss; $93.5M Cash on Hand - TradingView
KLRS: TH103 clinical progress and strong cash position support operations into Q4 2027 - TradingView
Kalaris Reports $11.5 Million Q2 Net Loss and TH103 Updates - Quiver Quantitative
Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates - marketscreener.com
BRIEF-Kalaris Therapeutics Inc Q2 Operating Income USD -12.386 Million Vs. IBES Estimate USD -12.5 Million - TradingView
Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates - Yahoo Finance
Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates - Barchart.com
Kalaris Therapeutics (KLRS) Slides 2.9% to $4.07 as Biotech Sellers Test Key SupportWeak Sell Signals - vinanet.vn
Kalaris Therapeutics Inc expected to post a loss of 49 cents a shareEarnings Preview - TradingView
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Kalaris Therapeutics (NASDAQ:KLRS) Shares Up 15.4%Here's What Happened - MarketBeat
KLRS: Abbott Cooper PLLC Announces Investigation on Behalf - GlobeNewswire
KLRS Q1 2026 Earnings: Narrower-than-Expected Loss Lifts SharesTangible Book Value - vinanet.vn
Kalaris Therapeutics (KLRS) Holds Gains Near $3.51 as Stock Consolidates Between Key LevelsValue Stock Ideas - dars.gov.et
Kalaris Therapeutics (KLRS) Holds Gains Near $3.51 as Stock Consolidates Between Key LevelsInstitutional Buy Signals - careplusvn.com
Kalaris Therapeutics (KLRS) Holds Gains Near $3.51 as Stock Consolidates Between Key LevelsSentiment Shift - vinanet.vn
KLRS Q1 2026 Earnings: Narrower-Than-Expected Loss Lifts Investor SentimentMargin Compression Risk - vinanet.vn
Kalaris Therapeutics (KLRS) Sees Modest Gain as Stock Holds Above SupportPCR Spike - vinanet.vn
Kalaris Therapeutics Inc (KLRS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Kalaris Therapeutics Inc (KLRS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Kalaris Therapeutics Inc (KLRS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Kalaris Therapeutics Inc (KLRS) Cash Flow - TradingKey
Kalaris Therapeutics Inc (KLRS) Valuation: PE, PB & Fair Value Analysis - TradingKey
KLRS Q1 2026 Earnings: Narrower-Than-Expected Loss Boosts Bottom Line Despite No RevenueNet Profit Margin - vinanet.vn
TradingKey - TradingKey
KLRS|Kalaris Therapeutics Inc|Price:3.730|Chg%:-0.190 - TradingKey
Kalaris Therapeutics Inc Stock (KLRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Kalaris Therapeutics Inc Stock (KLRS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hagen Brett R | Chief Accounting Officer |
Mar 20 '26 |
Sale |
6.72 |
1,915 |
12,869 |
0 |
| BRETT R R HAGEN | Officer |
Mar 20 '26 |
Proposed Sale |
6.72 |
1,915 |
12,869 |
0 |
| AKKARAJU SRINIVAS | Director |
Dec 18 '25 |
Buy |
10.42 |
479,847 |
5,000,006 |
1,979,847 |
3.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):